STOCK TITAN
  1. Home
  2. Sec-filings
  3. GALT
  4. [Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity

Galectin CEO option exercises at $2.39; sales avg $6.01 & $6.07

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Galectin Therapeutics (GALT) reported insider transactions by its President and CEO, who is also a Director. On 11/03/2025 and 11/04/2025, the officer exercised stock options at $2.39 per share for 1,300 and 14,420 shares, respectively, and sold the same number of common shares under a Rule 10b5-1 trading plan adopted on April 17, 2025. Sales were executed at weighted average prices of $6.01 (range: $6.00–$6.01) and $6.07 (range: $6.00–$6.20). Following these transactions, the officer directly beneficially owned 832,592 common shares and held 2,000 shares indirectly as custodian for a minor child under the UTMA. The reported options vested on December 14, 2018 and expire on December 14, 2027.

Positive

  • None.

Negative

  • None.
Insider LEWIS JOEL
Role President and CEO
Sold 15,720 shs ($95K)
Type Security Shares Price Value
Exercise Stock option (right to buy) 14,420 $0.00 --
Exercise Common Stock 14,420 $2.39 $34K
Sale Common Stock 14,420 $6.07 $88K
Exercise Stock option (right to buy) 1,300 $0.00 --
Exercise Common Stock 1,300 $2.39 $3K
Sale Common Stock 1,300 $6.01 $8K
holding Common Stock -- -- --
Holdings After Transaction: Stock option (right to buy) — 24,530 shares (Direct); Common Stock — 847,012 shares (Direct); Common Stock — 2,000 shares (Indirect, as USTA custodian for a minor child)
Footnotes (1)
  1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The options vested 100% on December 14, 2018. These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.20. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LEWIS JOEL
(Last) (First) (Middle)
C/O GALECTIN THERAPEUTICS INC.
4960 PEACHTREE INDUSTRIAL BLVD., STE 240
(Street)
NORCROSS GA 30071
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
11/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/03/2025 M(1) 1,300 A $2.39 833,892 D
Common Stock 11/03/2025 S(1) 1,300 D $6.01(2) 832,592 D
Common Stock 11/04/2025 M(1) 14,420 A $2.39 847,012 D
Common Stock 11/04/2025 S(1) 14,420 D $6.07(5) 832,592 D
Common Stock 2,000 I as USTA custodian for a minor child(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy) $2.39 11/03/2025 M(1) 1,300 12/14/2018(3) 12/14/2027 Common Stock 1,300 $0 38,950 D
Stock option (right to buy) $2.39 11/04/2025 M(1) 14,420 12/14/2018(3) 12/14/2027 Common Stock 14,420 $0 24,530 D
Explanation of Responses:
1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
2. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
3. The options vested 100% on December 14, 2018.
4. These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.
5. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.20. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Jack W. Callicutt, by power of attorney 11/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR